CH676715A5 - - Google Patents

Download PDF

Info

Publication number
CH676715A5
CH676715A5 CH3921/88A CH392188A CH676715A5 CH 676715 A5 CH676715 A5 CH 676715A5 CH 3921/88 A CH3921/88 A CH 3921/88A CH 392188 A CH392188 A CH 392188A CH 676715 A5 CH676715 A5 CH 676715A5
Authority
CH
Switzerland
Prior art keywords
group
mpl
acid
monophosphoryl lipid
hydrogen
Prior art date
Application number
CH3921/88A
Other languages
German (de)
English (en)
Inventor
Kent R Myers
Edgar E Ribi
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of CH676715A5 publication Critical patent/CH676715A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
CH3921/88A 1987-10-22 1988-10-21 CH676715A5 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/112,742 US4987237A (en) 1983-08-26 1987-10-22 Derivatives of monophosphoryl lipid A

Publications (1)

Publication Number Publication Date
CH676715A5 true CH676715A5 (enExample) 1991-02-28

Family

ID=22345625

Family Applications (1)

Application Number Title Priority Date Filing Date
CH3921/88A CH676715A5 (enExample) 1987-10-22 1988-10-21

Country Status (10)

Country Link
US (1) US4987237A (enExample)
JP (1) JPH075623B2 (enExample)
BE (1) BE1003250A5 (enExample)
CA (1) CA1308711C (enExample)
CH (1) CH676715A5 (enExample)
DE (1) DE3836006C2 (enExample)
FR (1) FR2622192A1 (enExample)
GB (1) GB2211502B (enExample)
IT (1) IT1230592B (enExample)
NL (1) NL8802595A (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158939A (en) * 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
FI920131A7 (fi) * 1989-07-14 1992-01-13 American Cyanamid Co Sytokiini- ja hormonikantajia konjugaattirokotteita varten
US5498708A (en) * 1989-07-18 1996-03-12 Montefiore Medical Center Method of synthesizing polyesters
CA2059272A1 (en) * 1990-04-12 1991-10-13 Akira Hasegawa 4,6-0-hydroxyphosphoryl-glucosamine derivatives
US5653974A (en) * 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
US5164375A (en) * 1991-09-27 1992-11-17 Merck & Company, Inc. Antifungal agent
US5648343A (en) * 1994-02-28 1997-07-15 The University Of Georgia Research Foundation Method for treating LPS-mediated disorders
US6218166B1 (en) 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US5681824A (en) * 1995-06-05 1997-10-28 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia
US6290971B1 (en) * 1995-06-15 2001-09-18 Aventis Pasteur Limited Adjuvant compositions comprising a mineral salt and another immunostimulating compound
GB9706957D0 (en) * 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20030139356A1 (en) 2001-05-18 2003-07-24 Persing David H. Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
ES2305086T3 (es) 2000-05-19 2008-11-01 Corixa Corporation Tratamiento profilactico y terapeutico de enfermedades alergicas, autoinmunes e infecciosas con compuestos con base de monosacaridos.
US20030138769A1 (en) * 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US20030175863A1 (en) * 2001-08-15 2003-09-18 Birkett Ashley J. Influenza immunogen and vaccine
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US20030185858A1 (en) * 2001-08-15 2003-10-02 Birkett Ashley J. Immunogenic HBc chimer particles stabilized with an N-terminal cysteine
ES2336080T3 (es) * 2002-02-04 2010-04-08 Corixa Corporation Nuevos compuestos inmunoefectores.
US6911434B2 (en) * 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
WO2003073827A2 (en) * 2002-02-28 2003-09-12 Corixa Corporation Methods of modulating dendritic cells using adjuvants
US20030224013A1 (en) * 2002-04-19 2003-12-04 Cole Garry T. Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
EP1521762B1 (en) 2002-07-08 2014-03-12 Corixa Corporation Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor
RU2389732C2 (ru) 2003-01-06 2010-05-20 Корикса Корпорейшн Некоторые аминоалкилглюкозаминидфосфатные производные и их применение
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
ATE324903T1 (de) * 2003-02-18 2006-06-15 Clinique La Prairie Res Sa Zusammensetzungen enthaltend fötales hämoglobin und bakterielles endotoxin und fakultativ zusätzliche fötale leberkomponenten
WO2006073921A2 (en) * 2004-12-30 2006-07-13 The Rockefeller University Compositions and methods for enhanced dendritic cell maturation and function
US20060210590A1 (en) 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP2486938B1 (en) 2006-09-26 2018-05-09 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
CA2695399C (en) 2007-08-02 2017-10-17 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
US20090215710A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Carbohydrate based toll-like receptor (tlr) antagonists
US20090215908A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Toll like receptor (tlr) signaling antagonist
AU2008331800A1 (en) 2007-12-03 2009-06-11 President And Fellows Of Harvard College Chlamydia antigens
MX360448B (es) * 2009-06-05 2018-11-01 Infectious Disease Res Inst Adyuvantes sinteticos de glucopiranosil-lipido.
AU2011360572B2 (en) 2011-02-22 2017-03-02 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
GB201106802D0 (en) 2011-04-21 2011-06-01 Allergy Therapeutics Ltd Process for preparing vaccine composition
ES2673556T3 (es) 2012-05-16 2018-06-22 Immune Design Corp. Vacunas para el VHS-2
AU2014214844B2 (en) 2013-02-07 2017-12-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
CN105658661B (zh) 2013-02-20 2020-07-24 卑尔根技术交易股份公司 疫苗
KR102039520B1 (ko) 2013-04-18 2019-11-01 이뮨 디자인 코포레이션 암 치료에 이용하기 위한 gla 단일요법
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US9919029B2 (en) 2013-07-26 2018-03-20 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of bacterial infections
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
SG11202002174SA (en) 2017-09-13 2020-04-29 Sanofi Pasteur Human cytomegalovirus immunogenic composition
US20190275134A1 (en) 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against urinary tract infections
US12527853B2 (en) 2018-08-24 2026-01-20 Vestlandets Innovasjonsselskap As (Vis) Heat-stable enterotoxins mutants as antidiarrheal vaccine antigens
KR20220107166A (ko) 2019-10-02 2022-08-02 얀센 백신스 앤드 프리벤션 비.브이. 스타필로코커스 펩티드 및 사용 방법
EP4090363B1 (en) 2020-01-16 2024-09-04 Janssen Pharmaceuticals, Inc. Fimh mutant, compositions therewith and use thereof
TW202241929A (zh) 2021-01-12 2022-11-01 美商詹森藥物公司 ＦｉｍＨ突變體、其組成物及其用途
WO2022208430A1 (en) 2021-04-01 2022-10-06 Janssen Pharmaceuticals, Inc. Production of e. coli o18 bioconjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0414725Y2 (enExample) * 1980-09-30 1992-04-02
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
JPS62129293A (ja) * 1985-11-28 1987-06-11 Toho Yakuhin Kogyo Kk 親水性のリピドａ単糖類縁体
JPS62195396A (ja) * 1986-02-20 1987-08-28 Toho Yakuhin Kogyo Kk 親水性及び疎水性の基を置換したりピドａ単糖類縁体

Also Published As

Publication number Publication date
CA1308711C (en) 1992-10-13
DE3836006A1 (de) 1989-05-03
GB2211502B (en) 1992-02-19
NL8802595A (nl) 1989-05-16
GB2211502A (en) 1989-07-05
GB8824330D0 (en) 1988-11-23
IT1230592B (it) 1991-10-28
FR2622192A1 (fr) 1989-04-28
JPH075623B2 (ja) 1995-01-25
DE3836006C2 (de) 1996-07-11
IT8822399A0 (it) 1988-10-21
US4987237A (en) 1991-01-22
FR2622192B1 (enExample) 1994-11-10
JPH01146891A (ja) 1989-06-08
JPH075623B1 (enExample) 1995-01-25
BE1003250A5 (fr) 1992-02-11

Similar Documents

Publication Publication Date Title
CH676715A5 (enExample)
DE2655500C2 (enExample)
EP0519327B1 (de) N-Acyl-S-(2-hydroxyalkyl)-cysteine, deren Herstellung sowie deren Verwendung als Zwischenprodukte zur Herstellung von synthetischen Immunadjuvantien und synthetischen Impfstoffen
DE69103255T2 (de) Säureempfindliche Linkermoleküle.
DE60023748T2 (de) Chlorophyll- und bacteriochlorophyllester, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE3122479A1 (de) N-(vinblastin-23-oyl)-aminosaeurederivate
DE3887820T2 (de) Antibiotika, Benanomicine A und B und Dexylosylbenanomicin B, ihre Herstellung und Verwendung.
US4304726A (en) Process for the preparation of cholesterol derivatives
DE3887362T2 (de) Thymopentin-Retro-Inverso-Analoga und deren Fragmente, Verfahren zu deren Herstellung und so erhaltene Zwischenprodukte.
DE69033257T2 (de) Zytotoxische zyklische Depsipeptide des Manteltierchen Trididemnum Solidum
EP0658585B1 (de) Amidinophenylalaninderivate, Verfahren zu deren Herstellung, deren Verwendung und diese enthaltende Mittel als Antikoagulantien
EP0060999B1 (de) Galactopyranoside Verbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Antigene oder Immunadsorbentien
DD210687A5 (de) Verfahren zur herstellung von (+)-cyanidan-3-ol-derivaten
DE68914418T2 (de) Lysoganglioside-Derivate.
DE2557145C3 (de) Tyrosinderivate, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel
DE69019217T2 (de) Perylenquinon (UCN-1028D)-Derivate.
US4225525A (en) Vitamin D3 metabolite derivatives
EP1603930A1 (de) Proteinbindende derivate von platinkomplexen mit cyclobutan-1,1-dicarboxylatliganden
EP0087751B1 (de) Wasserlösliche Peptide sehr schwer löslicher Aminosäuren
DE69004808T2 (de) Antibiotikum N-Acetylbenanomicin B, dessen Herstellung und Verwendung.
DE68913936T2 (de) Retro-Inverso-Thrymopentin-Analoge, Verfahren zu deren Herstellung und deren Verwendung für die Zubereitung von pharmazeutischen Zusammensetzungen.
DE69017771T2 (de) Thymopentin-Analoge mit allen umgekehrten Verbindungen, Verfahren zur deren Herstellung und deren Verwendung zur Herstellung von pharmazeutischen Zusammensetzungen.
DD262998A5 (de) Verfahren zur herstellung eines konjugates von einem vinca-alkaloid mit einem protein
CH628323A5 (de) Verfahren zur herstellung von cholecystokinin-pancreozymin-octapeptidamid-sulfatester.
EP1129107B1 (de) Verfahren zur herstellung von l-prolyl-l-m-sarcolysyl-l-p-fluorphenylalanin und von derivaten davon

Legal Events

Date Code Title Description
PFA Name/firm changed

Owner name: RIBI IMMUNOCHEM RESEARCH, INC.

Free format text: RIBI IMMUNOCHEM RESEARCH, INC.#N.E. 581 OLD CORVALLIS ROAD P.O. BOX 1409#HAMILTON/MT (US) -TRANSFERTO- RIBI IMMUNOCHEM RESEARCH, INC.#N.E. 581 OLD CORVALLIS ROAD P.O. BOX 1409#HAMILTON/MT (US)

PL Patent ceased